 | Up a level |
Rothschild, Sacha I; Betticher, Daniel; Zenhäusern, Reinhard; Anchisi, Sandro; von Moos, Roger; Pless, Miklos; Moosmann, Peter; Popescu, Razvan A; Calderoni, Antonello; Dressler, Marco; Rauch, Daniel; Pederiva, Stefanie; Woelky, Regina; Papet, Claudia; Bühler, Vera; Borner, Markus (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer chemotherapy and pharmacology, 84(4), pp. 881-889. Springer 10.1007/s00280-019-03927-x
Pestalozzi, Bernhard C; Tausch, Christoph; Dedes, Konstantin J; Rochlitz, Christoph; Zimmermann, Stefan; von Moos, Roger; Winterhalder, Ralph; Ruhstaller, Thomas; Mueller, Andreas; Buser, Katharina; Borner, Markus; Novak, Urban; Nussbaum, Catrina Uhlmann; Seifert, Bettina; Bigler, Martin; Bize, Vincent; Vilei, Simona Berardi; Rageth, Christoph; Aebi, Stefan (2017). Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer, 17(1), p. 265. BioMed Central 10.1186/s12885-017-3261-1
Kölzer, Viktor; Zlobec, Inti; Cathomas, Marionna Myrta; Dirschmid, Klaus; Offner, Felix; Puppa, Giacomo; Tornillo, Luigi; Berger, Martin Dave; Borner, Markus; Dawson, Heather; Hädrich, Marion; Mallaev, Makhmudbek; Schnüriger, Beat; Inderbitzin, Daniel; Lugli, Alessandro (1 September 2014). A multicentre inter-observer study on tumour budding using a 10HPF method in colorectal cancer: a study from the Swiss Association of Gastrointestinal Pathology (SAGIP) (Unpublished). In: European Congress of Pathology 2014. London, UK. 30.08.-03.09.2014.
Helbling, Melina; Lukesch, Anne Carolin; Haimovici, Aladin; Karamitopoulou, Evanthia; Berger, Martin Dave; Hädrich, Marion; Mallaev, Makhmud; Schnüriger, Beat; Kölzer, Viktor; Dawson, Heather; Borner, Markus; Langer, Rupert; Rosenberg, Robert; Nitsche, Ulrich; Inderbitzin, Daniel; Lugli, Alessandro; Tschan, Mario; Zlobec, Inti (2014). Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. OncoTarget, 5(13), pp. 4671-4682. Impact Journals LLC
Kölzer, Viktor H.; Lugli, Alessandro; Dawson, Heather; Hädrich, Marion; Berger, Martin D.; Borner, Markus; Mallaev, Makhmudbek; Galván Hernández, José Alberto; Amsler, Jennifer; Schnüriger, Beat; Zlobec, Inti; Inderbitzin, Daniel (2014). CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. Journal of translational medicine, 12(81), p. 81. BioMed Central 10.1186/1479-5876-12-81
Dawson, Heather; Hädrich, M.; Kölzer, V.; Inderbitzin, D.; Borner, M.; Zlobec, I.; Lugli, A. (2013). Intratumoral Budding (ITB) in Pre-Operative Biopsies: A Strong Indicator of Lymph Node Positivity in Colon and Rectal Cancer Patients. Laboratory investigation, 93(S1), 148A. Nature Publishing Group
Dawson, Heather; Hädrich, M.; Kölzer, V.; Inderbitzin, D.; Borner, M.; Zlobec, I.; Lugli, A. (2013). Intratumoral Budding (ITB) in Pre-Operative Biopsies:A Strong Indicator of Lymph Node Positivity in Colon and Rectal Cancer Patients. Modern pathology, 26, 148A. Nature Publishing Group
Dawson, Heather; Hädrich, Marion; Kölzer, Viktor; Borner, Markus; Mallaev, M.; Schnüriger, Beat; Inderbitzin, Daniel; Zlobec, Inti; Lugli, Alessandro (2013). Intratumoral budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastasis in colon and rectal cancer patients. Pathologe, 34(6), p. 602. Springer-Medizin-Verlag
Lugli, Alessandro; Hädrich, Marion; Inderbitzin, D; Borner, Markus; Zlobec, Inti (2012). Intratumoral budding is preoperative biopsies predicts local and distant metastasis in colorectal cancer patients. Virchows Archiv, 461(1 (Sup), S11. Springer
Karamitopoulou, Eva; Zlobec, Inti; Tornillo, Luigi; Carafa, Vincenza; Schaffner, Thomas; Brunner, Thomas; Borner, Markus; Diamantis, Ioannis; Zimmermann, Arthur; Terracciano, Luigi (2010). Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology, 42(3), pp. 229-34. London: Wolters Kluwer Lippincott Williams & Wilkins 10.3109/00313021003631379
Karamitopoulou, Eva; Pallante, Pierlorenzo; Zlobec, Inti; Tornillo, Luigi; Carafa, Vincenza; Schaffner, Thomas; Borner, Markus; Diamantis, Ioannis; Esposito, Francesco; Brunner, Thomas; Zimmermann, Arthur; Federico, Antonella; Terracciano, Luigi; Fusco, Alfredo (2010). Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. European journal of cancer, 46(8), pp. 1438-44. Amsterdam: Elsevier 10.1016/j.ejca.2010.01.033
Dufour, Jean-François; Hoppe, Hanno; Heim, Markus H; Helbling, Beat; Maurhofer, Olivier; Szucs-Farkas, Zsolt; Kickuth, Ralph; Borner, Markus; Candinas, Daniel; Saar, Bettina (2010). Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist, 15(11), pp. 1198-204. Miamisburg, Ohio: AlphaMed Press 10.1634/theoncologist.2010-0180
Ruhstaller, Thomas; Templeton, Arnoud; Ribi, Karin; Schuller, Jan C; Borner, Markus; Thierstein, Sandra; von Moos, Roger; Pederiva, Stefanie; Lohri, Andreas; Lombriser, Norbert; von Briel, Christian; Koeberle, Dieter; Popescu, Razvan (2010). Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie, 33(5), pp. 222-8. Basel: Karger 10.1159/000305094
Koeberle, Dieter; Montemurro, Michael; Samaras, Panagiotis; Majno, Pietro; Simcock, Mathew; Limacher, Andreas; Lerch, Stefanie; Kovàcs, Katalin; Inauen, Roman; Hess, Vivianne; Saletti, Piercarlo; Borner, Markus; Roth, Arnaud; Bodoky, György (2010). Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist, 15(3), pp. 285-92. Miamisburg, Ohio: AlphaMed Press 10.1634/theoncologist.2009-0316
Ruhstaller, T; Widmer, L; Schuller, J C; Roth, A; Hess, V; Mingrone, W; von Moos, R; Borner, M; Pestalozzi, B C; Balmermajno, S; Köberle, D; Terraciano, L; Schnider, A; Bodis, S; Popescu, R (2009). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology, 20(9), pp. 1522-8. Oxford: Oxford University Press 10.1093/annonc/mdp045
Cmelak, Anthony J; Lordick, Florian; Borner, Markus; Goldberg, Richard M; Saif, M Wasif (2009). Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology, 23(2 Suppl 1), pp. 18-25. Norwalk, Conn.: UBM Medica
Ribi, Karin; Koeberle, Dieter; Schuller, Jan C; Honegger, Hanspeter; Roth, Arnaud; Hess, Viviane; Moosmann, Peter; von Moos, Roger; Borner, Markus; Lombriser, Norbert; Pestalozzi, Bernhard; Ruhstaller, Thomas (2009). Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Supportive care in cancer, 17(8), pp. 1109-1116. Berlin: Springer 10.1007/s00520-008-0570-6
Karamitopoulou, Eva; Tornillo, Luigi; Zlobec, Inti; Cioccari, Lukas; Carafa, Vincenza; Borner, Markus; Schaffner, Thomas; Brunner, Thomas; Diamantis, Ioannis; Zimmermann, Arthur; Terracciano, Luigi (2008). Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. American journal of clinical pathology, 130(5), pp. 780-6. Chicago, Ill.: American Society for Clinical Pathology 10.1309/AJCP35FDCAVANWMM
Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, C; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, 19(7), pp. 1288-92. Oxford: Oxford University Press 10.1093/annonc/mdn058
Wagner, Oliver J; Inglin, Roman A; Bisch-Knaden, Sonja; Mettler, Daniel; Borner, Markus; Candinas, Daniel; Egger, Bernhard (2008). Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses. Transplant international, 21(6), pp. 554-63. Oxford: Wiley-Blackwell 10.1111/j.1432-2277.2007.00635.x
Koeberle, Dieter; Saletti, Piercarlo; Borner, Markus; Gerber, Daniela; Dietrich, Daniel; Caspar, Clemens B; Mingrone, Walter; Beretta, Kurt; Strasser, Florian; Ruhstaller, Thomas; Mora, Oreste; Herrmann, Richard (2008). Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 26(22), pp. 3702-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2008.16.5704
Sternberg, Cora N; Krainer, Michael; Oh, William K; Bracarda, Sergio; Bellmunt, Joaquim; Ozen, Haluk; Zlotta, Alexandre; Beer, Tomasz M; Oudard, Stephane; Rauchenwald, Michael; Skoneczna, Iwona; Borner, Markus M; Fitzpatrick, John M (2007). The medical management of prostate cancer: a multidisciplinary team approach. BJU international, 99(1), pp. 22-7. Oxford: Blackwell Science 10.1111/j.1464-410X.2006.06477.x
Roth, AD; Fazio, N; Stupp, R; Falk, S; Bernhard, J; Saletti, P; Köberle, D; Borner, MM; Rufibach, K; Maibach, R; Wernli, M; Leslie, M; Glynne-Jones, R; Widmer, L; Seymour, M; de Braud, F; Swiss, Group for Clinical Cancer Research (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 25(22), pp. 3217-23. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.08.0135
Salzberg, Marc; Rochlitz, Christoph; Morant, Rudolf; Thalmann, George; Pedrazzini, Augusto; Roggero, Enrico; Schönenberger, Astrid; Knuth, Alexander; Borner, Markus (2007). An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie, 30(7), pp. 355-60. Basel: Karger 10.1159/000102452
Helbling, D; Borner, M (2007). Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Annals of oncology, 18(5), pp. 963-4. Oxford: Oxford University Press 10.1093/annonc/mdm130
Tscharner, Gion Gudench; Bühler, Sabine; Borner, Markus; Hunziker, Thomas (2006). Grover's disease induced by cetuximab. Dermatology, 213(1), pp. 37-9. Basel: Karger 10.1159/000092836
Pirnia, Farzaneh; Frese, Steffen; Gloor, Beat; Hotz, Michel A; Luethi, Alexander; Gugger, Mathias; Betticher, Daniel C; Borner, Markus M (2006). Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. Anticancer research, 26(3A), pp. 1765-72. Kapandriti: International Inst. of Anticancer Research
Borner, M M (2006). [Molecular targets in colon cancer]. Therapeutische Umschau, 63(4), pp. 243-8. Bern: Huber 10.1024/0040-5930.63.4.243
Salzberg, Marc; Borner, Markus; Bauer, Jean-Alexandre; Morant, Rudolf; Rauch, Daniel; Rochlitz, Christoph (2006). Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. European journal of cancer, 42(15), pp. 2660-1. Amsterdam: Elsevier 10.1016/j.ejca.2006.06.009
Roth, A. D.; Maibach, R.; Fazio, N.; Sessa, C.; Stupp, R.; Morant, R.; Herrmann, R.; Borner, M. M.; Goldhirsch, A.; De Braud, F. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of oncology, 15(5), pp. 759-764. Oxford University Press 10.1093/annonc/mdh187
Tschan, Mario; Fischer, K. M.; Fung, V. S.; Pirnia Borner, Farzaneh; Borner, Markus; Fey, Martin; Tobler, Andreas; Torbett, B. E. (2003). Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns. Journal of biological chemistry, 278(44), pp. 42750-42760. American Society for Biochemistry and Molecular Biology 10.1074/jbc.M307067200
Waeber, M.; Castiglione-Gertsch, M.; Dietrich, D.; Thürlimann, B.; Goldhirsch, A.; Brunner, K. W.; Borner, M. M. (2003). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology, 14(8), pp. 1215-1221. Oxford University Press 10.1093/annonc/mdg347
Kralidis, E.; Aebi, S.; Friess, H.; Büchler, M. W.; Borner, M. M. (2003). Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Annals of oncology, 14(4), pp. 574-579. Oxford University Press 10.1093/annonc/mdg150
Scheithauer, W.; Mckendrick, J.; Begbie, S.; Borner, M.; Burns, W. I.; Burris, H. A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E. L.; Marschner, N.; Maroun, J.; Garcia-Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C. (2003). Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of oncology, 14(12), pp. 1735-1743. Oxford University Press 10.1093/annonc/mdg500
Scholz, M.; Zehender, M.; Thalmann, G. N.; Borner, M.; Thöni, H.; Studer, U. E. (2002). Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Annals of oncology, 13(1), pp. 121-124. Oxford University Press 10.1093/annonc/mdf003
Pirnia, Farzaneh; Borner, Markus M. (2002). RESPONSE: Multidrug-Resistant MCF-7 Cells: An Identity Crisis? Journal of the National Cancer Institute JNCI, 94(21), p. 1654. Oxford University Press 10.1093/jnci/94.21.1654
Crivellari, D.; Pagani, O.; Veronesi, A.; Lombardi, D.; Nolè, F.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Sessa, C.; Goldhirsch, A. (2001). High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology, 12(3), pp. 353-356. Oxford University Press 10.1023/A:1011132609055
Pagani, O.; Sessa, C.; Nolè, F.; Crivellari, D.; Lombardi, D.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Zucchetti, M.; D'Incalci, M.; Goldhirsch, A. (2000). Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study. Annals of oncology, 11(8), pp. 985-991. Oxford University Press 10.1023/A:1008392927656
Pirnia, Farzaneh; Breuleux, Madlaina; Schneider, Erasmus; Hochmeister, Manfred; Bates, Susan E.; Marti, Andreas; Hotz, Michel A.; Betticher, Daniel C.; Borner, Markus M. (2000). Uncertain Identity of Doxorubicin-Resistant MCF-7 Cell Lines Expressing Mutated p53. Journal of the National Cancer Institute JNCI, 92(18), pp. 1535-1536. Oxford University Press 10.1093/jnci/92.18.1535
Roth, A. D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M. S.; Pagani, O.; Morant, R.; Borner, M. M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch, A. (2000). Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. Annals of oncology, 11(3), pp. 301-306. Oxford University Press 10.1023/A:1008342013224
Pagani, O.; Sessa, C.; Martinelli, G.; Crivellari, D.; Buonadonna, A.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Zampino, G.; Zimatore, M.; Graffeo, R.; Riva, A.; Goldhirsch, A. (1999). Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology, 10(5), pp. 539-545. Oxford University Press 10.1023/A:1026437731354
Borner, M. M. (1999). Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true? Annals of oncology, 10(6), pp. 623-626. Oxford University Press 10.1023/A:1008353227103
Zahnd, D.; Aebi, S.; Rusterholz, S.; Fey, M. F.; Borner, M. M. (1999). A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Annals of oncology, 10(6), pp. 727-729. Oxford University Press 10.1023/A:1008334313918
Sessa, C.; Minoia, C.; Ronchi, A.; Zucchetti, M.; Bauer, J.; Borner, M.; De Jong, J.; Pagani, O.; Renard, J.; Weil, C.; D'Lncalci, M. (1998). Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Annals of oncology, 9(12), pp. 1315-1322. Oxford University Press 10.1023/A:1008441416790
Borner, M. M.; Castiglione, M.; Bacchi, M.; Weber, Walter; Herrmann, R.; Fey, M. F.; Pagani, O.; Leyvraz, S.; Morant, R.; Pestalozzi, B.; Hanselmann, S.; Goldhirsch, A. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of oncology, 9(5), pp. 535-541. Oxford University Press 10.1023/A:1008270916325
Maurer, Christoph A.; Borner, Markus M.; Läuffer, Jörg; Friess, Helmut; Z'Graggen, Kaspar; Triller, Jürgen; Büchler, Markus W. (1998). Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. International journal of pancreatology, 23(3), pp. 181-186. Humana Press 10.1007/BF02788395
